Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Liter Per Hour Per Square Meter

Known as: (l/h)/m2, L/h/m2, Liters per Hour per Square Meter 
A unit expressed as one liter of volume per unit of time equal to one hour per square meter of area.
National Institutes of Health

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys
PurposeTo characterize the pharmacokinetics of the prodrug, TH-302, and its active metabolite, bromo-IPM (Br-IPM), in nonclinical… Expand
  • figure 1
  • figure 2
  • table 2
  • figure 3
  • table 3
Highly Cited
2007
Highly Cited
2007
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic…
SummaryPurpose: SNS-032, (formerly BMS-387032) is a potent and selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9… Expand
  • table 1
  • table 3
  • figure 1
  • table 2
  • table 4
2007
2007
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan
Fludarabine is commonly used in combination with busulfan as part of conditioning regimens before allogeneic stem cell… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2004
Highly Cited
2004
Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study
PurposeLiposomal encapsulation of doxorubicin is designed to increase safety and tolerability by decreasing cardiac and… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 5
  • table 2
Highly Cited
2004
Highly Cited
2004
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients
BackgroundAprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting… Expand
  • figure 2
  • figure 1
  • table 1
  • table 2
  • table 3
Highly Cited
2001
Highly Cited
2001
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
BACKGROUND Previous work demonstrated that 5-fluorouracil (5-FU) metabolism is a critical factor for treatment tolerability. In… Expand
  • table I
  • figure I
  • figure 2
  • figure 3
2001
2001
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
OBJECTIVES This trial was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and… Expand
Highly Cited
2000
Highly Cited
2000
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
The aim of this study was to investigate the clinical pharmacokinetics of 5-fluorouracil (5-FU) and its major metabolite 5-fluoro… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
1999
1999
The effect of fluconazole on cyclophosphamide metabolism in children.
Fluconazole is increasingly used in children receiving chemotherapy. Many of these patients are being treated with… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
Highly Cited
1992
Highly Cited
1992
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days
Topotecan (SK&F 104864) is a novel antitumor agent whose mechanism of action is inhibition of the DNA unwinding protein… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE